{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:26:11Z","timestamp":1793042771882,"version":"4.5.0"},"reference-count":110,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Exploring the possible correlations between gene variations and the clinical effects of the new-generation antipsychotics is considered essential in the framework of personalized medicine. It is expected that pharmacogenetic data will be useful for increasing the treatment efficacy, tolerability, therapeutic adherence, functional recovery, and quality of life in patients with severe psychiatric disorders (SPD). This scoping review investigated the available evidence about the pharmacokinetics, pharmacodynamics, and pharmacogenetics of five new-generation antipsychotics, i.e., cariprazine, brexpiprazole, aripiprazole, lumateperone, and pimavanserin. Based on the analysis of 25 primary and secondary sources and the review of these agents\u2019 summaries of product characteristics, aripiprazole benefits from the most relevant data about the impact of gene variability on its pharmacokinetics and pharmacodynamics, with significant consequences on this antipsychotic\u2019s efficacy and tolerability. The determination of the CYP2D6 metabolizer status is important when administering aripiprazole, either as monotherapy or associated with other pharmacological agents. Allelic variability in genes encoding dopamine D2, D3, and serotonin, 5HT2A, 5HT2C receptors, COMT, BDNF, and dopamine transporter DAT1 was also associated with different adverse events or variations in the clinical efficacy of aripiprazole. Brexpiprazole also benefits from specific recommendations regarding the CYP2D6 metabolizer status and the risks of associating this antipsychotic with strong\/moderate CYP2D6 or CYP3A4 inhibitors. US Food and Drug Administration (FDA) and European Medicines Agency (EMA) recommendations about cariprazine refer to possible pharmacokinetic interactions with strong CYP3A4 inhibitors or inducers. Pharmacogenetic data about cariprazine is sparse, and relevant information regarding gene-drug interactions for lumateperone and pimavanserin is yet lacking. In conclusion, more studies are needed to detect the influence of gene variations on the pharmacokinetics and pharmacodynamics of new-generation antipsychotics. This type of research could increase the ability of clinicians to predict favorable responses to specific antipsychotics and to improve the tolerability of the treatment regimen in patients with SPD.<\/jats:p>","DOI":"10.3389\/fpsyt.2023.1124796","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T10:18:51Z","timestamp":1676542731000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["The pharmacogenetics of the new-generation antipsychotics \u2013 A scoping review focused on patients with severe psychiatric disorders"],"prefix":"10.3389","volume":"14","author":[{"given":"Octavian","family":"Vasiliu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/070674370404900504","article-title":"New antipsychotics, compliance, quality of life, and subjective tolerability- are patients better off?.","volume":"49","author":"Awad","year":"2004","journal-title":"Can J Psychiatry."},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11154530","article-title":"Second-generation antipsychotics\u2019 effectiveness and tolerability: a review of real-world studies in patients with schizophrenia and related disorders.","volume":"11","author":"Fabrazzo","year":"2022","journal-title":"J Clin Med."},{"key":"B3","year":"2021","journal-title":"Summary of product characteristics."},{"key":"B4","first-page":"13","article-title":"The role of pharmacogenetics and pharmacogenomics in improving translational medicine.","volume":"6","author":"Dere","year":"2009","journal-title":"Clin Cases Miner Bone Metab."},{"key":"B5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4021\/jocmr2009.08.1255","article-title":"Pharmacogenomics: the right drug to the right person.","volume":"1","author":"Aneesh","year":"2009","journal-title":"J Clin Med Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/mp.2009.89","article-title":"Genomewide pharmacogenomic analysis of response to treatment with antipsychotics.","volume":"16","author":"McClay","year":"2011","journal-title":"Mol Psychiatry."},{"key":"B7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/sj.mp.4002009","article-title":"Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.","volume":"12","author":"Arranz","year":"2007","journal-title":"Mol Psychiatry."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104965","article-title":"Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: systematic review and meta-analysis of randomised controlled trials.","volume":"144","author":"Arnone","year":"2023","journal-title":"Neurosci Biobehav Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1185\/03007995.2015.1063483","article-title":"Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation.","volume":"31","author":"Winner","year":"2015","journal-title":"Curr Med Res Opin."},{"key":"B10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000445802","article-title":"Genetics of common antipsychotic-induced adverse effects.","volume":"2","author":"MacNeil","year":"2016","journal-title":"Mol Neuropsychiatry."},{"key":"B11","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41397-021-00249-1","article-title":"Economic evaluation in psychiatric pharmacogenomics: a systematic review.","volume":"21","author":"Karamperis","year":"2021","journal-title":"Pharmacogenomics J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00406-021-01358-5","article-title":"Detailing the effects of polypharmacy in psychiatry: longitudinal study of 320 patients hospitalized for depression or schizophrenia.","volume":"272","author":"Stassen","year":"2022","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"B13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.55453\/rjmm.2020.123.1.1","article-title":"Efficacy and tolerability of antibiotic augmentation in schizophrenia spectrum disorders- A systematic literature review.","author":"Vasiliu","year":"2020","journal-title":"RJMM."},{"key":"B14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.55453\/rjmm.2018.121.2.4","article-title":"Therapeutic management of schizophrenia and substance use disorders dual diagnosis- clinical vignettes.","author":"Vasiliu","year":"2018","journal-title":"RJMM."},{"key":"B15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1001\/archgenpsychiatry.2009.175","article-title":"National trends in psychotropic medication polypharmacy in office-based psychiatry.","volume":"67","author":"Mojtabai","year":"2010","journal-title":"Arch Gen Psychiatry."},{"key":"B16","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1001\/jamapsychiatry.2017.0624","article-title":"Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia.","volume":"74","author":"Correll","year":"2017","journal-title":"JAMA Psychiatry."},{"key":"B17","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/00008571-200310000-00003","article-title":"Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.","volume":"13","author":"Floyd","year":"2003","journal-title":"Pharmacogenetics."},{"key":"B18","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/YCO.0b013e32835d9efb","article-title":"Polypharmacy for schizophrenia.","volume":"26","author":"Ballon","year":"2013","journal-title":"Curr Opin Psychiatry."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000492332","article-title":"Pharmacogenetics of antipsychotic drug treatment: update and clinical implications.","volume":"5","author":"Yoshida","year":"2020","journal-title":"Mol Neuropsychiatry."},{"key":"B20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.55453\/rjmm.2018.121.1.4","article-title":"Analysis of risk factors for antipsychotic-resistant schizophrenia in young patients- a retrospective analysis.","author":"Vasiliu","year":"2018","journal-title":"RJMM."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00402","article-title":"Treatment-resistant schizophrenia: genetic and neuroimaging correlates.","volume":"10","author":"Vita","year":"2019","journal-title":"Front Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2147\/PGPM.S142314","article-title":"ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine.","volume":"10","author":"Piatkov","year":"2017","journal-title":"Pharmacogenomics Pers Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/15622975.2020.1747112","article-title":"Therapeutic drug monitoring and pharmacogenetics of antipsychotics and antidepressants in real life settings: a 5-year single centre experience.","volume":"22","author":"Baldelli","year":"2021","journal-title":"World J Biol Psychiatry."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41397-022-00292-6","article-title":"Clinical utility of pharmacogenetics in a psychiatric and primary care population.","author":"Bohlen","year":"2022","journal-title":"Pharmacogenomics."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/jpm10040204","article-title":"Variant interpretation in current pharmacogenetic testing.","volume":"10","author":"Luvsantseren","year":"2020","journal-title":"J Pers Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2217\/pgs-2016-0164","article-title":"Clinicians\u2019 perceptions of pharmacogenomics use in psychiatry.","volume":"18","author":"Chan","year":"2017","journal-title":"Pharmacogenomics."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10184275","article-title":"Review: influence of the CYP450 genetic variation on the treatment of psychotic disorders.","volume":"10","author":"Carrascal-Laso","year":"2021","journal-title":"J Clin Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1602\/neurorx.2.1.86","article-title":"Blood-brain barrier active efflux transporters: ATP-binding cassette gene family.","volume":"2","author":"L\u00f6scher","year":"2005","journal-title":"NeuroRx."},{"key":"B29","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/bcp.12441","article-title":"Addressing phenoconversion: the Achilles\u2019 heel of personalized medicine.","volume":"79","author":"Shah","year":"2015","journal-title":"Br J Clin Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1177\/070674371405900203","article-title":"Pharmacogenetics of antipsychotics.","volume":"59","author":"Brandl","year":"2014","journal-title":"Can J Psychiatry."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41525-018-0065-4","article-title":"User considerations in assessing pharmacogenomic tests and their clinical support tools.","volume":"2","author":"Mukerjee","year":"2018","journal-title":"NPJ Genom Med."},{"key":"B32","year":"2023","journal-title":"Genes."},{"key":"B33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/cts.12598","article-title":"Effects of common CYP1A2 genotypes and other key factors on intraindividual variation in the caffeine metabolic ratio: an exploratory analysis.","volume":"12","author":"Tian","year":"2019","journal-title":"Clin Transl Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/FPC.0b013e32834c6efd","article-title":"PharmGKB summary: very important pharmacogene information for CYP1A2.","volume":"22","author":"Thorn","year":"2012","journal-title":"Pharmacogenet Genom."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01717-9","article-title":"Methodology for clinical genotyping of CYP2D6 and CYP2C19.","volume":"11","author":"Henriques","year":"2021","journal-title":"Transl Psychiatry."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01591-5","article-title":"Genetic polymorphism of CYP2C19 and subcortical variability in the human adult brain.","volume":"11","author":"Stingl","year":"2021","journal-title":"Transl Psychiatry."},{"key":"B37","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1161\/ATVBAHA.118.311963","article-title":"Clinical utility of CYP2C19 genotyping to guide antiplatelet therapy in patients with an acute coronary syndrome or undergoing percutaneous coronary intervention.","volume":"39","author":"Klein","year":"2019","journal-title":"Arterioscler Tromb Vasc Biol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/clpt.2013.2","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.","volume":"93","author":"Hicks","year":"2013","journal-title":"Clin Pharmacol Ther."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00432","article-title":"Consequences of CYP2D6 copy-number variation for pharmacogenomics in psychiatry.","volume":"10","author":"Jarvis","year":"2019","journal-title":"Front Psychiatry."},{"key":"B40","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/cpt.2149","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy.","volume":"110","author":"Crews","year":"2021","journal-title":"Clin Pharmacol Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/cts.12692","article-title":"Standardized CYP2D6 genotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and Dutch pharmacogenetics working group.","volume":"13","author":"Caudle","year":"2020","journal-title":"Clin Transl Sci."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8040094","article-title":"Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates.","volume":"8","author":"Saiz-Rodr\u00edguez","year":"2020","journal-title":"Biomedicines."},{"key":"B43","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1097\/FTD.0b013e31815c16f5","article-title":"Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring.","volume":"29","author":"Zhou","year":"2007","journal-title":"Ther Drug Monit."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.711943","article-title":"CYP3A4*22 genotyping in clinical practice: ready for implementation?.","volume":"12","author":"Mulden","year":"2021","journal-title":"Front Genet."},{"key":"B45","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/JCP.0000000000000070","article-title":"The influence of the CYP3A4*22 polymorphism on serum concentration of quetiapine in psychiatric patients.","volume":"34","author":"van der Weide","year":"2014","journal-title":"J Clin Psychopharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s40262-015-0289-8","article-title":"Genetics-based population pharmacokinetics and pharmacodynamics of risperidone in a psychiatric cohort.","volume":"54","author":"Vanderberghe","year":"2015","journal-title":"Clin Pharmacokinet."},{"key":"B47","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/tpj.2017.38","article-title":"The predictive value of ABCB1, ABCG2, CYP3A4\/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions.","volume":"18","author":"Rafaniello","year":"2018","journal-title":"Pharmacogenetics J."},{"key":"B48","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/FPC.0b013e3283385a1c","article-title":"Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).","volume":"21","author":"Hodges","year":"2011","journal-title":"Pharmacogenet Genomics."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1248\/bpb.25.1391","article-title":"MDR1 genotype-related pharmacokinetics and pharmacodynamics.","volume":"25","author":"Sakeda","year":"2002","journal-title":"Biol Pharm Bull."},{"key":"B50","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/bcpt.13031","article-title":"Effect of ABCB1 C3435T polymorphism on pharmacokinetics of antipsychotics and antidepressants.","volume":"123","author":"Saiz-Rodr\u00edguez","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1067\/mcp.2002.126177","article-title":"Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein.","volume":"72","author":"Kurata","year":"2002","journal-title":"Clin Pharmacol Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1046\/j.1472-8206.2003.00163.x","article-title":"MDR1 polymorphism G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes.","volume":"17","author":"Oselin","year":"2003","journal-title":"Fundam Clin Pharmacol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/JCP.0b013e3181acc372","article-title":"ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.","volume":"29","author":"Sirot","year":"2009","journal-title":"J Clin Psychopharmacol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2217\/pgs.12.86","article-title":"Antipsychotic drug dosage and therapeutic response in schizophrenia is influenced by ABCB1 genotypes: a study from a south Indian perspective.","volume":"13","author":"Vijayan","year":"2012","journal-title":"Pharmacogenomics."},{"key":"B55","doi-asserted-by":"publisher","first-page":"323","DOI":"10.31887\/DCNS.2016.18.3\/jbishop","article-title":"Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations.","volume":"18","author":"Eum","year":"2016","journal-title":"Dialogues Clin Neurosci."},{"key":"B56","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2217\/pgs.15.171","article-title":"Candidate gene analysis of pharmacodynamic targets for antipsychotic dosage.","volume":"17","author":"Hettige","year":"2016","journal-title":"Pharmacogenomics."},{"key":"B57","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.schres.2015.12.015","article-title":"Polygenic risk score prediction of antipsychotic dosage in schizophrenia.","volume":"170","author":"Hettige","year":"2016","journal-title":"Schizophr Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1093\/schbul\/sbx007","article-title":"Polygenic risk score for schizophrenia and treatment-resistant schizophrenia.","volume":"43","author":"Wimberley","year":"2017","journal-title":"Schizophr Bull."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.psyneuen.2016.06.002","article-title":"Variants in the DRD2 locus and antipsychotic-related prolactin levels: a meta-analysis.","volume":"72","author":"Miura","year":"2016","journal-title":"Psychoneuroendocrinology."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.2217\/pgs.16.26","article-title":"Pharmacogenetics of tardive dyskinesia: an updated review of the literature.","volume":"17","author":"Lanning","year":"2016","journal-title":"Pharmacogenomics."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1093\/schbul\/sbw058","article-title":"Pharmacogenetic associations of antipsychotic drug-related weight gain: a systematic review and meta-analysis.","volume":"42","author":"Zhang","year":"2016","journal-title":"Schizophr Bull."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.786171","article-title":"Case report: cariprazine efficacy in young patients diagnosed with schizophrenia with predominantly negative symptoms.","volume":"12","author":"Vasiliu","year":"2021","journal-title":"Front Psychiatry."},{"key":"B63","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1177\/1060028020936597","article-title":"Lumateperone: a novel antipsychotic for schizophrenia.","volume":"55","author":"Greenwood","year":"2021","journal-title":"Ann Pharmacother."},{"key":"B64","first-page":"368","article-title":"Pimavanserin (Nuplazid).","volume":"42","author":"Cruz","year":"2017","journal-title":"P T."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.884143","article-title":"Investigational drugs for the treatment of depression (Part 1): monoaminergic, orexinergic, GABA-ergic, and anti-inflammatory agents.","volume":"13","author":"Vasiliu","year":"2022","journal-title":"Front Pharmacol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S2215-0366(19)30088-4","article-title":"Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole : a retrospective, cohort study.","volume":"6","author":"Jukic","year":"2019","journal-title":"Lancet Psychiatry."},{"key":"B67","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s40263-015-0278-3","article-title":"Update on the mechanism of action of aripirpazole: translational insights into antipsychotic strategies beyond dopamine receptor antagonism.","volume":"29","author":"de Bartolomeis","year":"2015","journal-title":"CNS Drugs."},{"key":"B68","year":"2014","journal-title":"Summary of product characteristics."},{"key":"B69","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2165\/00003495-200464150-00010","article-title":"Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.","volume":"64","author":"Harrison","year":"2004","journal-title":"Drugs."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13070935","article-title":"Review of pharmacokinetics and pharmacogenetics in atypical long-acting injectable antipsychotics.","volume":"13","author":"Toja-Camba","year":"2021","journal-title":"Pharmaceutics."},{"key":"B71","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/bcpt.12960","article-title":"Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 polymorphisms on pharmacokinetics and safety of aripiprazole in healthy volunteers.","volume":"122","author":"Belmonte","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/jcpt.12780","article-title":"Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes: a systematic review and meta-analysis.","volume":"44","author":"Zhang","year":"2019","journal-title":"J Clin Pharm Ther."},{"key":"B73","year":"2009","journal-title":"Summary of product characteristics."},{"key":"B74","year":"2018","journal-title":"Summary of product characteristics."},{"key":"B75","year":"2017","journal-title":"Summary of product characteristics."},{"key":"B76","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00228-019-02768-0","article-title":"Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status.","volume":"76","author":"Tveito","year":"2020","journal-title":"Eur J Clin Pharmacol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2217\/17410541.5.4.361","article-title":"Pharmacogenetic testing of CYP2D6 in patients with aripiprazole-related extrapyramidal symptoms: a case-control study.","volume":"5","author":"Surja","year":"2008","journal-title":"Per Med."},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-017-1396-x","article-title":"Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report.","volume":"17","author":"Eum","year":"2017","journal-title":"BMC Psychiatry."},{"key":"B79","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.euroneuro.2008.07.010","article-title":"Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole.","volume":"18","author":"Kwon","year":"2008","journal-title":"Eur Neuropsychopharmacol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00213-009-1538-z","article-title":"HTR2A A-1438G\/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients.","volume":"205","author":"Chen","year":"2009","journal-title":"Psychopharmacology."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hup.2761","article-title":"Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised controlled clinical trial.","volume":"36","author":"Koller","year":"2021","journal-title":"Hum Psychopharmacol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1089\/cap.2020.0058","article-title":"CYP2D6 phenotype influences aripiprazole tolerability in pediatric patients with mood disorders.","volume":"31","author":"Jallaq","year":"2021","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/npp.2017.298","article-title":"Dopaminergic genetic variation influences aripiprazole effects on alcohol self-administration and the neural response to alcohol cues in a randomized trial.","volume":"43","author":"Schacht","year":"2018","journal-title":"Neuropsychopharmacology."},{"key":"B84","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2217\/pgs-2020-0024","article-title":"The pharmacogenetics of aripiprazole-induced hyperprolactinemia: what do we know?.","volume":"21","author":"Koller","year":"2020","journal-title":"Pharmacogenomics."},{"key":"B85","doi-asserted-by":"publisher","first-page":"869","DOI":"10.2217\/pgs.14.50","article-title":"Pharmacogenetics of second-generation antipsychotics.","volume":"15","author":"Brennan","year":"2014","journal-title":"Pharmacogenomics."},{"key":"B86","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1177\/1099800409358760","article-title":"Functional SNPs in genes encoding the 5-HT2A receptor modify the affinity and potency of several atypical antipsychotic drugs.","volume":"13","author":"Davies","year":"2011","journal-title":"Biol Res Nurs."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s12325-020-01566-w","article-title":"Metabolic effects of aripiprazole and olanzapine multiple-dose treatment in a randomised crossover clinical trial in healthy volunteers: association with pharmacogenetics.","volume":"38","author":"Koller","year":"2021","journal-title":"Adv Ther."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1092852915000954","article-title":"Mechanism of action of brexpiprazole: comparison with aripiprazole.","volume":"21","author":"Stahl","year":"2016","journal-title":"CNS Spectr."},{"key":"B89","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/2045125315614739","article-title":"Brexpiprazole: so far so good.","volume":"6","author":"Das","year":"2016","journal-title":"Ther Adv Psychopharmacol."},{"key":"B90","year":"","journal-title":"Summary of product characteristics."},{"key":"B91","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1080\/00498254.2021.1897898","article-title":"In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole.","volume":"51","author":"Sasabe","year":"2021","journal-title":"Xenobiotica."},{"key":"B92","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1017\/S1092852916000043","article-title":"Mechanism of action of cariprazine.","volume":"21","author":"Stahl","year":"2016","journal-title":"CNS Spectr."},{"key":"B93","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/s41386-019-0590-6","article-title":"positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, and serotonin reuptake transporters in subjects with schizophrenia.","volume":"45","author":"Girgis","year":"2020","journal-title":"Neuropsychopharmacology."},{"key":"B94","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1007\/s00213-016-4382-y","article-title":"Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3\/D2 receptor ligand [11C](+)-PHNO.","volume":"233","author":"Girgis","year":"2016","journal-title":"Psychopharmacology."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1177\/2045125320905752","article-title":"Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data.","volume":"10","author":"Stahl","year":"2020","journal-title":"Ther Adv Psychopharmacol."},{"key":"B96","article-title":"In vivo dopamine D3 and D2 receptor occupancy profile of cariprazine versus aripiprazole: a PET study.","volume":"42","author":"Girgis","year":"2018","journal-title":"Neuropsychopharmacology."},{"key":"B97","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine d(3) receptor-preferring, D(3)\/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.","volume":"333","author":"Kiss","year":"2010","journal-title":"J Pharmacol Exp Ther."},{"key":"B98","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1517\/17425255.2013.759211","article-title":"Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability.","volume":"9","author":"Citrome","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s13318-020-00650-4","article-title":"Population pharmacokinetics of cariprazine and its major metabolites.","volume":"46","author":"Periclou","year":"2021","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"B100","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.2147\/DDDT.S188760","article-title":"Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine.","volume":"13","author":"Kiss","year":"2019","journal-title":"Drug Des Devel Ther."},{"key":"B101","year":"2015","journal-title":"Summary product characteristics."},{"key":"B102","year":"2017","journal-title":"Summary of product characteristics."},{"key":"B103","year":"2019","journal-title":"Summary of product characteristics."},{"key":"B104","year":"2016","journal-title":"Summary of product characteristics."},{"key":"B105","year":"2022","journal-title":"CPIC guidelines published, in progress, or planned."},{"key":"B106","year":"","journal-title":"Clinical guideline annotations."},{"key":"B107","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/ajmg.b.32736","article-title":"International society of psychiatric genetics ethics committee: issues facing us.","volume":"180","author":"L\u00e1zaro-Mu\u00f1oz","year":"2019","journal-title":"Am J Med Genet B Neuropsychiatr Genet."},{"key":"B108","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/a-1288-1061","article-title":"review and consensus on pharmacogenomic testing in psychiatry.","volume":"54","author":"Bousman","year":"2021","journal-title":"Pharmacopsychiatry."},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-018-0330-4","article-title":"Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics.","volume":"8","author":"Boloc","year":"2018","journal-title":"Transl Psychiatry."},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-019-0254-y","article-title":"Delineating significant genome-wide associations of variants with antipsychotic and antidepressant treatment response: implications for clinical pharmacogenomics.","volume":"14","author":"Koromina","year":"2020","journal-title":"Hum Genomics."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1124796\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T10:19:00Z","timestamp":1676542740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1124796\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":110,"alternative-id":["10.3389\/fpsyt.2023.1124796"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1124796","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,16]]},"article-number":"1124796"}}